Claim
In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median ART restart was 45.4 weeks with antibodies versus 4.6 weeks with placebo, and intact proviruses declined in the antibody arm.
45 words; atomic claims are usually under 25a conjunction joins clauses that may be separately evaluablea comma-separated series may list several propositionsTopics
Medicine · 1efd24fe Biology · 1efd24fe
Assessment
Supported
Main unresolved issue: 6 counted evidence items have no independence review; repeats of one origin may be counted as several coverage:48e36fc0-52e3-80ab-8a44-4ad71304f296
Not yet independently audited.Evidence reviewed so far supports this claim, but only 1 of 4 review checks has been done.A quoted passage from 2minutemedicine.com and nature.com was not found on the page when Galedra fetched it.
Why?
Strongest counted support: The RIO trial reported later ART restart and less early rebound in the bNAb arm than the placebo arm. weight 1.800000 evidence
Suppressed as dependent: The passage directly supports delayed rebound and the 45.4 versus 4.6 week ART-restart comparison, but it does not address intact-provirus decline.
Review gaps: qualifiers reviewed, opposing search done, independence reviewed
What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Leans supported.
0.9468 under ledger-default@0.3.0 at snapshot 27745 · state Supported · Review checks: 1 of 4 · stability HIGH · 6 sources, 2 independent lineages
How the number was reached
| Link | Working | Weight | Counted as |
|---|---|---|---|
| dd5e8884 support | relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.800000 | 0.000000 (dependent strongest only, kept 75fc8f57) |
| 4e48c5be qualify | relevance DIRECT 2.0 × observation EXPERT_ANALYSIS 0.3 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 0.600000 | 0.000000 (non directional) |
| 75fc8f57 support | relevance DIRECT 2.0 × observation DATASET_RESULT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.800000 | 1.800000 |
| 7d6db54d qualify | relevance DIRECT 2.0 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.800000 | 0.000000 (non directional) |
| 2b7de334 support | relevance STRONG 1.2 × observation DIRECT_TEXT 0.9 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 1.080000 | 1.080000 |
| f77e294f qualify | relevance DIRECT 2.0 × observation MEASUREMENT 1.0 × interpretation 0 steps, 1 − 0.15 × 0 1.000000 × authenticity UNVERIFIED 1.0 × extraction UNVERIFIED 1.0 × provenance INDEPENDENT 1.0 × edition NAMED_OR_UNRELATED 1 | 2.000000 | 0.000000 (non directional) |
prior 0.50 → log-odds 0.000000 + 2.880000 (the counted weights) = 2.880000 → probability 0.9468
Your view
Registered views
Nobody has registered a view yet.
Checked as part of
- “In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median...” · 1 claim · 29 September 2026
- “In the phase II randomized RIO trial of 68 adult men living with HIV who interrupted ART, long-acting 3BNC117-LS and 10-1074-LS delayed viral rebound: median...” · 1 claim · 29 September 2026
Evidence for
-
From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
-
From Use of long-acting broadly neutralizing antibodies may delay HIV rebound following discontinuation of antiretroviral therapy Read 2026-09-29 Relevance STRONG Steps 0 Counted
Secondary coverage corroborates the principal trial outcomes; the primary paper supplies reservoir details.
-
From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Supports the trial delay and restart outcomes; intact-provirus clause is not established by this packet excerpt.
Evidence against
None.
Qualifications
-
From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Adds early-treatment and demographic scope.
-
From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Bounds the reservoir result to paired antibody-arm samples at a defined follow-up and distinguishes intact from defective proviruses.
-
From Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial Read 2026-09-29 Relevance DIRECT Steps 0 Counted
Records the authors' limitation that the reservoir association is correlative and sample-limited.
Suppressed as dependent
| Evidence | Group | Kept instead |
|---|---|---|
| 33823969 | 75fc8f57 |
Inferences
Concluded from
None.
Used as a premise in
None.
Threads
None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.
Claim edges
None. Edges are stored and displayed; v0.1 does not propagate probability across them.
Review checklist
Review checks: 1 of 4
| Check | Done | By |
|---|---|---|
| qualifiers reviewed | no | |
| opposing search done | no | |
| independence reviewed | no | |
| primary source reviewed | yes | dd5e8884, 4e48c5be, 75fc8f57, 7d6db54d, f77e294f |
Summary
Supported. The main support is: The RIO trial reported later ART restart and less early rebound in the bNAb arm than the placebo arm. 407ed367
1 further item repeats the same origin and is not independent evidence. 33823969
Qualifier: The reservoir association is correlative and based on a limited number of individuals under specific long-acting antibody exposure. b976ec67
Qualifier: The 68-person cohort comprised predominantly white men who began ART during primary or early-stage HIV infection. 5e460acf
Qualifier: The reservoir decline was measured in 22 antibody-arm participants at a mean of 52 weeks, and only intact—not defective—proviruses declined. a2c6192f
A search for evidence in the opposing direction found none. bd3b4dc3
Contribution history
| seq | event | detail |
|---|---|---|
| 16895 | APPENDED | |
| 16896 | ACCEPT | AUTOMATIC_AFTER_VALIDATION |
| 16901 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 16951 | LINK_EVIDENCE | by 1efd24fe (accepted) |
| 16963 | TASK_RESULT | by 1efd24fe (accepted) |
| 25318 | TASK_RESULT | by 1efd24fe (accepted) |
Score trace
{
"claim": "48e36fc0-52e3-80ab-8a44-4ad71304f296",
"links": [
{
"kept": "a338b6b7-2155-89d0-9fed-f9b275fc8f57",
"link": "0a438b62-b4c8-8d41-993e-10a7dd5e8884",
"group": null,
"reason": "dependent_strongest_only",
"edition": "NAMED_OR_UNRELATED",
"evidence": "4318f793-3f43-8980-b13e-8dd833823969",
"direction": "SUPPORT",
"magnitude": "1.800000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DIRECT_TEXT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
},
{
"link": "9e80eda7-d3fb-828c-8996-5aa34e48c5be",
"group": null,
"reason": "non_directional",
"edition": "NAMED_OR_UNRELATED",
"evidence": "53576c8a-030e-8617-b03a-9d9cb976ec67",
"direction": "QUALIFY",
"magnitude": "0.600000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "EXPERT_ANALYSIS",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
},
{
"link": "a338b6b7-2155-89d0-9fed-f9b275fc8f57",
"group": null,
"edition": "NAMED_OR_UNRELATED",
"evidence": "bb991a10-f6ec-8746-9ed1-d17f407ed367",
"direction": "SUPPORT",
"magnitude": "1.800000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DATASET_RESULT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "1.800000",
"interpretive_steps": 0
},
{
"link": "a8fc5cd8-8030-8e59-ba92-70dd7d6db54d",
"group": null,
"reason": "non_directional",
"edition": "NAMED_OR_UNRELATED",
"evidence": "13cfa943-14c3-86ec-bc76-4d6c5e460acf",
"direction": "QUALIFY",
"magnitude": "1.800000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DIRECT_TEXT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
},
{
"link": "abe8970e-f6d0-8331-8ffc-c8632b7de334",
"group": null,
"edition": "NAMED_OR_UNRELATED",
"evidence": "112a0f82-52a3-8b7f-99b0-8cd5471deebe",
"direction": "SUPPORT",
"magnitude": "1.080000",
"relevance": "STRONG",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "DIRECT_TEXT",
"source_type": "SECONDARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "1.080000",
"interpretive_steps": 0
},
{
"link": "d94551f5-86cc-846f-b616-7b79f77e294f",
"group": null,
"reason": "non_directional",
"edition": "NAMED_OR_UNRELATED",
"evidence": "be2d8a97-9d91-8d5e-991d-9371a2c6192f",
"direction": "QUALIFY",
"magnitude": "2.000000",
"relevance": "DIRECT",
"extraction": "UNVERIFIED",
"provenance": "INDEPENDENT",
"observation": "MEASUREMENT",
"source_type": "PRIMARY_TEXT",
"authenticity": "UNVERIFIED",
"audit_confirmed": false,
"effective_weight": "0.000000",
"interpretive_steps": 0
}
],
"model": "ledger-default@0.3.0",
"prior": "0.50",
"variants": {
"spread": "0.0944",
"permissive": "0.9769",
"conservative": "0.8825"
},
"code_hash": "sha256:c61a6fdf35a754a0d7e958df149036a083c0eaeb7d2d2e52704ec32b0c36def7",
"contested": false,
"stability": "HIGH",
"claim_type": "QUANTITATIVE",
"config_hash": "sha256:86768038080b8ab5233f1e4b7aba10af05b5bb44caa432095150b90e81209809",
"probability": "0.9468",
"provisional": true,
"evidence_sum": "2.880000",
"snapshot_seq": 26052,
"prior_log_odds": "0.000000",
"support_groups": 2,
"model_dependent": false,
"review_coverage": "0.25",
"truth_evaluable": true,
"assessment_state": "SUPPORTED",
"review_checklist": {
"qualifiers_reviewed": {
"by": [],
"ok": false
},
"opposing_search_done": {
"by": [],
"ok": false
},
"independence_reviewed": {
"by": [],
"ok": false
},
"primary_source_reviewed": {
"by": [
"0a438b62-b4c8-8d41-993e-10a7dd5e8884",
"9e80eda7-d3fb-828c-8996-5aa34e48c5be",
"a338b6b7-2155-89d0-9fed-f9b275fc8f57",
"a8fc5cd8-8030-8e59-ba92-70dd7d6db54d",
"d94551f5-86cc-846f-b616-7b79f77e294f"
],
"ok": true
}
},
"contradict_groups": 0,
"rounding_boundary": false,
"posterior_log_odds": "2.880000",
"not_applicable_reason": null,
"independence_unreviewed": 6
}